[25] |
Fan L,Li J,Zhang H,et al.Machine learning analysis for the noninvasive prediction of lymphovascular invasion in gastric cancer using PET/CT and enhanced CT-based radiomics and clinical variables[J]. Abdom Radiol (NY),2022,47(4):1209-1222.
|
[26] |
Findlay JM,Antonowicz S,Segaran A,et al.Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery[J].Eur Radiol,2019,29(5): 2490-2498.
|
[27] |
Perlaza P,Ortín J,Pagès M,et al.Should 18F-FDG PET/CT Be Routinely Performed in the Clinical Staging of Locally Advanced Gastric Adenocarcinoma? [J].Clin Nucl Med,2018,43(6):402-410.
|
[28] |
Baek JH,Park DJ,Kim GY,et al.Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer[J].Anticancer Res, 2019,39(12):6973-6979.
|
[29] |
Cao W,Xing H,Li Y,et al.Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy[J].Biomark Res,2022, 10(1):38.
|
[30] |
Rohde C,Yamaguchi R,Mukhina S,et al. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma[J].Jpn J Clin Oncol,2019,49(9): 870-876.
|
[1] |
Wang S,Qi C,Ding J,et al.First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection[J]. Eur J Nucl Med Mol Imaging,2023,50(9):2802-2817.
|
[2] |
Sato Y,Okamoto K,Kawano Y,et al.Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives[J].J Clin Med,2023,12(14):4646.
|
[3] |
Jiang H,Shi Z,Wang P,et al.Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer[J].J Natl Cancer Inst,2019,111(4):409-418.
|
[4] |
Qi C,Gong J,Li J,et al.Claudin18.2-specific CAR T cells in gastrointestinal cancers:phase 1 trial interim results[J].Nat Med,2022, 28(6):1189-1198.
|
[5] |
Entezam M,Sanaei MJ,Mirzaei Y,et al.Current progress and challenges of immunotherapy in gastric cancer:A focus on CAR-T cells therapeutic approach[J].Life Sci,2023,318:121459.
|
[6] |
Zhao C,Rong Z,Ding J,et al.Targeting Claudin 18.2 Using a Highly Specific Antibody Enables Cancer Diagnosis and Guided Surgery[J].Mol Pharm,2022,19(10):3530-3541.
|
[7] |
Hu G,Zhu W,Liu Y,et al.Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer:a preclinical study[J].Eur J Nucl Med Mol Imaging,2022,49(8):2634-2644.
|
[8] |
Smyth EC,Nilsson M,Grabsch HI,et al. Gastric cancer[J].Lancet, 2020,396(10251):635-648.
|
[9] |
Machlowska J,Baj J,Sitarz M,et al.Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies[J].Int J Mol Sci,2020,21(11):4012.
|
[10] |
Kinami S,Nakamura N,Tomita Y,et al.Precision surgical approach with lymph-node dissection in early gastric cancer[J].World J Gastroenterol,2019,25(14):1640-1652.
|
[11] |
Hiramatsu Y,Takeuchi H,Goto O,et al.Minimally Invasive Function-Preserving Gastrectomy with Sentinel Node Biopsy for Early Gastric Cancer[J].Digestion.
|
[12] |
Linghu E.A new stage of surgical treatment: super minimally invasive surgery[J].Chin Med J (Engl),2022,135(1):1-3.
|
[13] |
Liu Q,Ding L,Qiu X,et al.Updated evaluation of endoscopic submucosal dissection versus surgery for early gastric cancer:A systematic review and meta-analysis[J].Int J Surg,2020,73(1):28-41.
|
[14] |
Song WC,Qiao XL,Gao XZ.A comparison of endoscopic submucosal dissection (ESD) and radical surgery for early gastric cancer: a retrospective study[J].World J Surg Oncol,2015,13(1):309.
|
[15] |
Quero G,Fiorillo C,Longo F,et al.Propensity score-matched comparison of short- and long-term outcomes between surgery and endoscopic submucosal dissection (ESD) for intestinal type early gastric cancer (EGC) of the middle and lower third of the stomach: a European tertiary referral center experience[J].Surg Endosc,2021,35(6):2592-2600.
|
[16] |
Park KB,Jeon CH,Seo HS,et al.Operative safety of curative gastrectomy after endoscopic submucosal dissection (ESD) for early gastric cancer - 1:2 propensity score matching analysis: A retrospective single-center study (cohort study) [J].Int J Surg,2020,80(1):124-128.
|
[17] |
Fujishiro M,Yoshida S,Matsuda R, et al.Updated evidence on endoscopic resection of early gastric cancer from Japan[J].Gastric Cancer, 2017,20(Suppl 1):39-44.
|
[18] |
Lee GH,Lee E,Park B,et al.Long-term outcomes of endoscopic submucosal dissection and surgery for undifferentiated intramucosal gastric cancer regardless of size[J].World J Gastroenterol,2022,28(8): 840 -852.
|
[19] |
Chu YN,Yu YN,Jing X,et al.Feasibility of endoscopic treatment and predictors of lymph node metastasis in early gastric cancer[J].World J Gastroenterol,2019,25(35):5344-5355.
|
[20] |
Akiyama Y,Katai H,Kitabayashi R,et al.Frequency of lymph node metastasis according to tumor location in clinical T1 early gastric cancer: supplementary analysis of the Japan Clinical Oncology Group study (JCOG0912) [J]. J Gastroenterol,2023,58(6):519-526.
|
[21] |
Hanada Y,Choi AY,Hwang JH,et al.Low Frequency of Lymph Node Metastases in Patients in the United States With Early-stage Gastric Cancers That Fulfill Japanese Endoscopic Resection Criteria[J].Clin Gastroenterol Hepatol,2019,17(9):1763-1769.
|
[22] |
Duan K,Li D,Shi D,et al.Risk Factors and Timing of Additional Surgery after Noncurative ESD for Early Gastric Cancer[J].Can J Gastroenterol Hepatol,2022,2022:3421078.
|
[23] |
Hatta W,Gotoda T,Koike T,et al.History and future perspectives in Japanese guidelines for endoscopic resection of early gastric cancer[J]. Dig Endosc,2020,32(2):180-190.
|
[24] |
Sekiguchi M,Suzuki H,Oda I,et al.Risk of recurrent gastric cancer after endoscopic resection with a positive lateral margin[J].Endoscopy, 2014,46(4):273-278.
|